Medicsight Inc.

Medicsight Inc. Files American Stock Exchange Application, Appoints Three Independent Directors, Establishes Audit Committee

    London (ots/PRNewswire) - Medicsight Inc. (OTC Bulletin Board: MSHT) announced today that on November 30, 2004 it forwarded its application to transfer the Company's listing from the OTC Bulletin Board to the American Stock Exchange to Cohen Specialists LLC, who deposited it with the American Stock Exchange on December 6, 2004.

    New Directors

    It was also announced that the Company has appointed three independent directors, Sir Christopher Paine, Peter Venton and Neal Wyman, to its Board of Directors.

    Sir Christopher Paine and Peter Venton are independent directors of Medicsight Inc.'s majority owned subsidiary Medicsight PLC.

    Neal Wyman trained as a chartered accountant (ACA) with Coopers and Lybrand before moving to KPMG where he worked in the Far East. He moved into the recruitment industry in London specialising in financial services, gaining experience with a diverse range of clients. He entered executive search in 1981, initially specialising in the financial services industry before broadening into general appointments and professional services. He now focuses on general management, finance and non-executive appointments in both private and quoted companies, with particular focus on venture capital. He is a graduate of the London School of Economics.

    Audit Committee

    On November 25, 2004 the Board of Directors of Medicsight, Inc. established an Audit Committee and adopted the Audit Committee Charter. The Board also adopted the Company's Code of Ethics.

    Subsequently Neal Wyman, Peter Venton and Professor Nadey Hakim, all being independent directors, were appointed to serve on the Audit Committee. The Audit Committee had their first meeting on November 26, 2004 and approved both the Audit Committee Charter and the Company's Code of Ethics.

    Neal Wyman will chair the Audit Committee and the Company can certify that Mr. Wyman fulfills the requirements for a member of the Audit Committee to be financially sophisticated.

    About Medicsight

    Medicsight is a software development business focused on the medical imaging market. The company is using its core technology to develop automatic detection and analytical tools for clinicians to improve their ability to diagnose and treat disease, initially focusing on three key clinical areas -- lung cancer, colon cancer, and coronary heart disease. Medicsight's software will enable earlier and more accurate detection and treatment of suspicious lesions, which can save lives and reduce healthcare costs. Headquartered in London, Medicsight employs more than 60 people and has offices in the U.K., United States, and China. Product and company information can be found on . Stock symbol: OTCBB: MSHT

    All forward-looking statements are made pursuant to the 'safe harbor' provisions of the Private Securities litigation Reform Act of 1995. Forward-looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission.

    Web site:

ots Originaltext: Medicsight Inc.
Im Internet recherchierbar:

James Whale of Medicsight, +44-20-7598-4070,

Weitere Meldungen: Medicsight Inc.

Das könnte Sie auch interessieren: